Business Wire

Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption

2.6.2025 14:00:00 CEST | Business Wire | Press Release

Share

Adtran today launched the latest additions to its Oscilloquartz optical cesium portfolio, expanding access to precision timing across a wider range of network environments. The new OSA 3200 SP and OSA 3250 ePRC leverage advanced optical pumping technology, offering improved holdover, simplified maintenance and a typical lifetime of 10 years. Built on the same proven platform as Adtran’s high-end cesium models, the solutions enable telecom operators, data centers, power utilities and defense networks to modernize synchronization infrastructure while lowering operational complexity and cost. The new models also address industry demand for alternatives to legacy magnetic cesium clocks that are more difficult to manage over time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530192819/en/

Adtran’s OSA 3200 SP and OSA 3250 ePRC will bring lower-cost optical pumping cesium technology to new markets and applications.

“We developed the OSA 3200 SP and OSA 3250 ePRC to make our industry-leading optical pumping cesium technology more accessible,” said Gil Biran, GM of Oscilloquartz, Adtran. “As the only vendor in the industry offering optical pumping cesium solutions, we’re uniquely positioned to support customers facing supply chain risk and escalating performance demands. By leveraging our existing high-end platform, we've engineered lower-cost solutions that enable more operators to benefit from the accuracy, longevity and modern manageability needed to keep critical timing infrastructure resilient and secure – whether at the network core, in distributed data centers or across mission-critical environments.”

The OSA 3200 SP addresses the need for a cost-optimized PRC-class cesium clock with standard performance, while the OSA 3250 ePRC is tailored for PNT applications that demand enhanced holdover capabilities. The OSA 3200 SP is a standard-performance cesium clock, part of a widely recognized industry classification that includes standard performance (SP), high performance (HP) and super high performance (SHP) levels.

The OSA 3200 SP and OSA 3250 ePRC share more than 95% of their electronics with Adtran’s flagship OSA 3300 and 3350 models, minimizing operational risk, streamlining inventory and ensuring deployment compatibility. Both solutions offer a 10-year service life – two years longer than typical magnetic ePRC clocks – and feature a design that places laser components outside the vacuum chamber. A compact physics package, enabled by unique patented technology, simplifies servicing and lowers system cost. Integrated support for SNMPv3, SSH and syslog is built in via a native TCP/IP stack, while compatibility with Adtran’s Mosaic Sync Director enables centralized visibility and control. With multiple timing outputs and secure remote management, these clocks are ready for rapid, scalable deployment.

“Our new solutions offer a more cost-effective route to scalable, sustainable timing,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “We’re extending the reach of our unique optical pumping cesium innovation to customers who need standard performance and high reliability at a much lower cost. As legacy magnetic clocks become harder to support, the OSA 3200 SP and 3250 ePRC provide a reliable, long-term foundation based on much more advanced technology – easier to manage, easier to service and fully integrated into the modern synchronization ecosystem. Whether for telecom operators, power utilities, transportation, hyperscalers or other markets, these new solutions bring optical cesium technology to entirely new applications.”

Further information on the OSA 3200 SP and OSA 3250 ePRC is available in these slides.

Adtran’s Oscilloquartz OSA 3250 ePRC will be on display from June 3 to 4 at the Joint Navigation Conference 2025 in Cincinnati, Ohio, USA.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250530192819/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye